Education
About Us
Working with TipRanks
Follow Us
Puma Biotechnology (PBYI)
NASDAQ:PBYI
PBYI Stock Chart & Stats
$4.88
-$0.12(-3.21%)
At close: 4:00 PM EST
$4.88
-$0.12(-3.21%)
Day’s Range― - ―
52-Week Range$2.58 - $6.12
Previous CloseN/A
Volume522.58K
Average Volume (3M)590.25K
Market Cap
$246.16M
Enterprise Value$215.01M
Total Cash (Recent Filing)$94.39M
Total Debt (Recent Filing)$41.05M
Price to Earnings (P/E)6.6
Beta0.71
Next Earnings
Feb 26, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.17
Shares Outstanding50,391,106
10 Day Avg. Volume928,576
30 Day Avg. Volume590,252
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.61
Price to Sales (P/S)0.64
P/FCF Ratio3.82
Enterprise Value/Market Cap0.87
Enterprise Value/Revenue1.01
Enterprise Value/Gross Profit1.32
Enterprise Value/Ebitda4.29
Forecast
1Y Price Target
$3.50Price Target Upside-28.28% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)0.49
Revenue Forecast (FY)$216.00M
Bulls Say, Bears Say
Bulls Say
Analyst ConfidencePuma's price target was adjusted upwards from $4.00 to $5.00, suggesting increased confidence in future performance.
EarningsPuma reported Q3 Nerlynx sales of $51.9MM, which was above consensus estimates of $47.5MM.
Financial OutlookThe company raised its FY 2025 revenue and net income guidance slightly, indicating a positive outlook.
Bears Say
Product ConfidenceThere is a lack of confidence in alisertib, and the recommendation remains at Hold.
Revenue ChallengesSignificant accelerations in product and royalty revenue are needed in Q4 to support the full year guidance.
Puma Biotechnology News
PBYI FAQ
What was Puma Biotechnology’s price range in the past 12 months?
Puma Biotechnology lowest stock price was $2.58 and its highest was $6.12 in the past 12 months.
What is Puma Biotechnology’s market cap?
Puma Biotechnology’s market cap is $246.16M.
When is Puma Biotechnology’s upcoming earnings report date?
Puma Biotechnology’s upcoming earnings report date is Feb 26, 2026 which is in 97 days.
How were Puma Biotechnology’s earnings last quarter?
Puma Biotechnology released its earnings results on Nov 06, 2025. The company reported $0.17 earnings per share for the quarter, beating the consensus estimate of $0.045 by $0.125.
Is Puma Biotechnology overvalued?
According to Wall Street analysts Puma Biotechnology’s price is currently Overvalued.
Does Puma Biotechnology pay dividends?
Puma Biotechnology does not currently pay dividends.
What is Puma Biotechnology’s EPS estimate?
Puma Biotechnology’s EPS estimate is 0.19.
How many shares outstanding does Puma Biotechnology have?
Puma Biotechnology has 50,391,106 shares outstanding.
What happened to Puma Biotechnology’s price movement after its last earnings report?
Puma Biotechnology reported an EPS of $0.17 in its last earnings report, beating expectations of $0.045. Following the earnings report the stock price went up 22.245%.
Which hedge fund is a major shareholder of Puma Biotechnology?
Currently, no hedge funds are holding shares in PBYI
Puma Biotechnology Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Sell
Average Price Target:
$3.50 (-28.28% Downside)
$3.50 (-28.28% Downside)
Blogger Sentiment
Bullish
PBYI Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.4K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $97.2K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 9.2%
Last 30 Days ▲ 9.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
78.28%
12-Months-Change
Fundamentals
Return on Equity
39.69%
Trailing 12-Months
Asset Growth
-8.09%
Trailing 12-Months
Company Description
Puma Biotechnology
Puma Biotechnology, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative products to enhance cancer care. Primarily operating in the pharmaceutical and biotechnology sectors, the company is dedicated to discovering and advancing novel therapeutics for the treatment of various cancer types. Its core product, NERLYNX (neratinib), is a leading oral medication designed to treat HER2-positive breast cancer and has been approved by the FDA for commercial use.
PBYI Company Deck
PBYI Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflects a balanced sentiment. While positive trends such as increased U.S. net sales of NERLYNX and positive net income indicate financial stability, challenges remain with declining royalty revenues and new prescriptions. Clinical trials are progressing well, but international sales and new patient starts pose significant hurdles.View all PBYI earnings summariesPBYI Stock 12 Month Forecast
Average Price Target
$3.50
▼(-28.28% Downside)
Technical Analysis
Heron Therapeutics
―
Voyager Therapeutics
―
Foghorn Therapeutics
―
Vor Biopharma
―
Tenaya Therapeutics
―
Ownership Overview
16.07% Insiders
13.85% Mutual Funds
10.83% Other Institutional Investors
47.19% Public Companies and
Individual Investors